Drug Trial Radar · NCT03547908
Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults
Last checked: Nov 20, 2026Latest source record: Mar 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
244
Actual
Start
May 30, 2018
Primary completion
Feb 25, 2022
Study completion Mar 7, 2024
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Jun 6, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the efficacy of fixed-dose combination (FDC) of bictegravir/emtricitabine/ tenofovir alafenamide (B/F/TAF) versus dolutegravir (DTG) + emtricitabine/tenofovir disoproxil fumarate (F/TDF) in treatment-naïve and HIV-1 and hepatitis B virus (HBV) adults.
Conditions
- HIV-1/HBV Co-Infection
Interventions
B/F/TAFDrug
50/200/25 mg B/F/TAF FDC tablet administered orally once daily, without regard to food
Placebo to match DTGDrug
Tablet administered orally once daily, without regard to food
Placebo to match F/TDFDrug
Tablet administered orally once daily, without regard to food
DTGDrug
50 mg tablet administered orally once daily, without regard to food
F/TDFDrug
200/300 mg tablet administered orally once daily, without regard to food
Placebo to match B/F/TAFDrug
Tablet administered orally once daily, without regard to food
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm (Co-primary Endpoint)Time frame: Week 48
- Percentage of Participants With Plasma Hepatitis B Virus (HBV) DNA < 29 IU/mL at Week 48 as Defined by Missing = Failure Approach (Co-primary Endpoint)Time frame: Week 48
Locations
69 sites in 14 countries. Site status is shown where the registry gives one.
Midway Immunology & Research
Ft. Pierce, Florida
Triple O Research Institute, P.A.
West Palm Beach, Florida
Be Well Medical Center
Berkley, Michigan
The Crofoot Research Center, INC (DBA: Gordon E. Crofoot MD PA)
Houston, Texas
Beijing Ditan Hospital Capital Medical University
Beijing, China
Beijing YouAn Hospital, Capital Medical University
Beijing, China
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, China
The First Hospital of Changsha
Changsha, China
Chengdu Public Health Clinical Center
Chengdu, China
Guangzhou Eighth people's Hospital
Guangzhou, China
1st Affiliated Hospital of Zhejiang University
Hangzhou, China
The Second Hospital of Nanjing
Nanjing, China
Shanghai Public Health Clinical Center
Shanghai, China
Third People's Hospital Of Shenzhen
Shenzhen, China
Instituto Dominicano de Estudios Virologicos (IDEV)
Santo Domingo, Dominican Republic
Hôpital de la Croix Rousse
Lyon, France
Evaggelismos General Hospital of Athens
Athens, Greece
Korgialenio-Benakio Greek Red Cross General Hospital
Athens, Greece
Laiko General Hospital
Athens, Greece
AHEPA University Hospital of Thessaloniki
Thessaloniki, Greece
Prince of Wales Hospital
Hong Kong, Hong Kong
Queen Elizabeth Hospital (QEH)
Hong Kong, Hong Kong
Princess Margaret Hospital
Kowloon, Hong Kong
National Hospital Organization Nagoya Medical Center
Aichi, Japan
University of the Ryukyus Hospital
Okinawa, Japan
Osaka City General Hospital
Osaka, Japan
National Hospital Organization Osaka National Hospital
Osaka, Japan
The Jikei University Hospital
Tokyo, Japan
Juntendo University Hospital
Tokyo, Japan
Center Hospital of the National Center for Global Health and Medicine
Tokyo, Japan
Yokohama City University Hospital
Yokohama, Japan
Hospital Raja Permaisuri Bainun
Ipoh, Malaysia
Hospital Raja Perempuan Zainab II
Kota Bharu, Malaysia
Queen Elizabeth Hospital
Kota Kinabalu, Malaysia
University Malaya Medical Centre
Kuala Lumpur, Malaysia
Hospital Kuala Lumpur
Kuala Lumpur, Malaysia
Hospital Sultanah Nur Zahirah
Kuala Terengganu, Malaysia
Sarawak General Hospital
Kuching, Malaysia
Hospital Pulau Pinang
Pulau Pinang, Malaysia
Sungai Buloh Hospital
Sungai Buloh, Malaysia
Showing 40 of 69 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.